trial

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

NCTId NCT05326347
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Active Not Recruiting
Enrollment 190 (estimated)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2025-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Active Not Recruiting
Enrollment
190 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-05-31
Primary completion
2025-08
Eligibility
ALL · 18 Years · 74 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Takeshi TsunodaStudy Director

Sites

1 total
Kure-shi, Japan

Linked catalysts

1
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation i — primary completion2025-08

Facts & assertions

4 sourced
Enrollment
190
Phase
PHASE3
Primary Completion Date
2025-08
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Takeshi Tsunoda
person